Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil
NCT02371395 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2018-10-23
Summary
Worldwide, approximately 2 billion people live in areas at risk for malaria with morbidity surpassing 250 million cases, with approximately 800,000 deaths, per year. Of the four species of malaria parasites that cause human infection, P. falciparum is responsible for the majority of severe malaria cases followed by P. vivax. Early and accurate diagnosis is essential for prompt and correct treatment, which can reduce the death rate and interrupt transmission. Currently, conventional methods for the diagnosis of malaria include microscopic examination of thin and thick blood smears and rapid diagnostic tests (RDTs). Light microscopy in practice typically detects parasitemia as low as 100 parasites/µl and it can differentiate species. The advantage of microscopy includes the ability to estimate parasitemia, the possibility to identify parasite stages, including gametocytes, and its low cost. However, this method is labor intensive, difficult to standardize, and requires well-trained microscopists. The majority of RDTs are based on detection of P. falciparum histidine-rich protein 2 (HRP-2) antigen and do not detect all malaria species. RDTs that detect lactose dehydrogenase (LDH) and aldolase generally broadly react with all four species of malaria parasites and therefore cannot differentiate among the species although efforts are underway to improve their performance for species detection. In settings where multiple malaria species co-circulate, molecular methods may be more reliable than microscopy and RDTs in accurately diagnosing the species of malaria parasites with low parasitemias. However, conventional molecular methods, such as nested polymerase chain reaction (nested PCR) or real-time PCR, are technically challenging and resource intensive and are generally restricted to reference laboratories due to the need for well-equipped laboratories. Recently, new molecular methods that can be used in field settings have been developed and this opens up new opportunities for exploring molecular tools for malaria diagnosis in endemic countries. With the objective of facilitating use of molecular tools for malaria control programs, the malaria laboratory at the Centers for Disease Control and Prevention (CDC) in Atlanta, USA developed a simple isothermal molecular method called Real-Time Fluorescence Loop-Mediated Isothermal Amplification (RealAmp) for the diagnosis of malaria. Currently, RealAmp primers exist for detecting the Plasmodium genus and the detection of P. falciparum and P. vivax species. The RealAmp method has great potential as a molecular tool for the diagnosis of malaria in the field (and other infections of major public health impact, such as HIV and tuberculosis). It can provide an alternative to conventional PCR-based diagnostic methods for field use in clinical and operational programs. The objective of this proposal is to validate the sensitivity of RealAmp for detection of malaria parasites in blood spots from patients with clinical diagnosis of malaria in two endemic states of Brazil with co-circulation of P. falciparum and P. vivax. In this evaluation, RealAmp and microscopic examination will be compared to a real-time PCR method as a reference test.
Conditions
- Malaria Diagnosis
Interventions
- OTHER
-
Realtime amplification (RealAmp)
Molecular assay for the diagnosis of malaria.
Sponsors & Collaborators
-
Evandro Chagas Institute of Clinical Research
collaborator OTHER -
Centers for Disease Control and Prevention
lead FED
Principal Investigators
-
Alexandre Macedo de Oliveira, MD · Centers for Disease Control and Prevention
Eligibility
- Min Age
- 7 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-31
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
Countries
- Brazil
Study Locations
More Related Trials
-
Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines
NCT00121823 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
NCT00317980 ·Status: COMPLETED ·Phase: PHASE4
-
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
NCT02639299 ·Status: RECRUITING
-
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
NCT01310738 ·Status: TERMINATED ·Phase: PHASE4
-
Malaria Vaccine for Children in Mali
NCT00740090 ·Status: COMPLETED ·Phase: PHASE1
-
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
NCT01422954 ·Status: COMPLETED ·Phase: NA
-
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
NCT00344539 ·Status: COMPLETED ·Phase: PHASE1
-
Experimental Vaccine for Malaria in Adults in Mali
NCT00343005 ·Status: COMPLETED ·Phase: PHASE1
-
ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
NCT03132402 ·Status: COMPLETED
-
Plasmodium Falciparum Genomic Intelligence in Mozambique
NCT05306067 ·Status: COMPLETED
-
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
NCT00349713 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B
NCT02458092 ·Status: COMPLETED ·Phase: PHASE1
-
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
NCT06613997 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Malaria Challenge in Healthy Volunteers
NCT01500980 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
NCT00312663 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
NCT00870987 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection
NCT01002833 ·Status: COMPLETED ·Phase: NA
-
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
NCT00487916 ·Status: COMPLETED ·Phase: PHASE1
-
Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults
NCT01624961 ·Status: COMPLETED ·Phase: PHASE1
-
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
NCT02530697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Low Antimonial Dosage in American Mucosal Leishmaniasis
NCT01301937 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali
NCT00863408 ·Status: COMPLETED
-
Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
NCT06040346 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
NCT00312702 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
NCT06069544 ·Status: COMPLETED ·Phase: PHASE1/PHASE2